Werewolf Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Werewolf Therapeutics
HOWL Stock  USD 1.16  0.01  0.85%   
Werewolf Therapeutics financial statements provide useful quarterly and yearly information to potential Werewolf Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Werewolf Therapeutics financial statements helps investors assess Werewolf Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Werewolf Therapeutics' valuation are summarized below:
Gross Profit
-51.2 M
Market Capitalization
52.4 M
Enterprise Value Revenue
0.6742
Revenue
1.9 M
Earnings Share
(1.63)
There are over one hundred nineteen available fundamental gauges for Werewolf Therapeutics, which can be analyzed over time and compared to other ratios. We recommend to confirm Werewolf Therapeutics' prevalent fundamental drivers against the all of the trends between 2010 and 2025. The value of Market Cap is estimated to slide to about 60.9 M. Enterprise Value is expected to rise to about (35.2 M) this year

Werewolf Therapeutics Total Revenue

1.79 Million

Check Werewolf Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Werewolf Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 1.5 M, Depreciation And Amortization of 1.1 M or Interest Expense of 4.9 M, as well as many indicators such as Price To Sales Ratio of 35.72, Dividend Yield of 0.0 or PTB Ratio of 0.92. Werewolf financial statements analysis is a perfect complement when working with Werewolf Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Werewolf Therapeutics Correlation against competitors.
For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.

Werewolf Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets139.2 M126.9 M68.4 M
Slightly volatile
Short and Long Term Debt Total18.1 M11 M9.1 M
Slightly volatile
Other Current Liabilities8 M10.6 M3.7 M
Slightly volatile
Total Current Liabilities14.3 M15.2 M6.9 M
Slightly volatile
Other Liabilities26.5 K27.9 K4.6 M
Slightly volatile
Property Plant And Equipment Net12.4 M12.3 M6.9 M
Slightly volatile
Accounts Payable1.7 M3 M1 M
Slightly volatile
Cash118 M112.2 M57.7 M
Slightly volatile
Non Current Assets Total17.5 M13.9 M9.1 M
Slightly volatile
Non Currrent Assets Other1.5 M1.5 M1.8 M
Slightly volatile
Other Assets1.091.15949 K
Pretty Stable
Cash And Short Term Investments118 M112.2 M57.7 M
Slightly volatile
Common Stock Total Equity2.5 K3.5 K2.2 K
Slightly volatile
Common Stock Shares Outstanding35.4 M43.9 M30.4 M
Slightly volatile
Liabilities And Stockholders Equity139.2 M126.9 M68.4 M
Slightly volatile
Non Current Liabilities Total39.7 M38.4 M45.8 M
Very volatile
Capital Lease Obligations10.9 M11 M6.2 M
Slightly volatile
Other Current Assets808.5 K851 K1.1 M
Slightly volatile
Other Stockholder Equity326 M488 M131.6 M
Slightly volatile
Total Liabilities50.1 M53.5 M52.5 M
Pretty Stable
Property Plant And Equipment Gross9.9 M17.3 M5.9 M
Slightly volatile
Total Current Assets121.7 M113.1 M59.2 M
Slightly volatile
Capital Stock3.3 K5 K2.5 K
Slightly volatile
Non Current Liabilities Other15.2 M14.5 M4.2 M
Slightly volatile
Net Working Capital107.4 M97.9 M52.3 M
Slightly volatile
Short Term Debt1.5 M1.6 M1.5 M
Slightly volatile
Common Stock3.3 K5 K2.5 K
Slightly volatile
Property Plant Equipment8.8 M10.3 M5.7 M
Slightly volatile
Deferred Long Term Liabilities124 K139.5 K152.1 K
Slightly volatile
Capital Surpluse459.1 M493.4 M417.4 M
Slightly volatile
Current Deferred Revenue775.5 K816.3 K5.5 M
Slightly volatile
Net Receivables1.2 M1.2 M5.9 M
Slightly volatile
Inventory1.61.81.9625
Slightly volatile
Long Term Debt23.5 M26.1 M31.7 M
Slightly volatile
Short and Long Term Debt5.3 M6 M6.5 M
Slightly volatile

Werewolf Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.1 M1.8 M714.4 K
Slightly volatile
Interest Expense4.9 M4.7 M1.1 M
Slightly volatile
Selling General Administrative14.8 M19 M8 M
Slightly volatile
Other Operating Expenses53.3 M75.5 M27.1 M
Slightly volatile
Research Development38.5 M56.4 M19.1 M
Slightly volatile
Cost Of Revenue47 M44.7 M8.7 M
Slightly volatile
Total Operating Expenses53.3 M75.5 M27.1 M
Slightly volatile
Reconciled Depreciation922.2 K1.8 M386.1 K
Slightly volatile
Interest Income7 M6.7 M1.3 M
Slightly volatile
Preferred Stock And Other Adjustments121.6 M136.7 M149.1 M
Slightly volatile
Non Operating Income Net Other1.3 M2.6 M601 K
Slightly volatile
Selling And Marketing Expenses1.4 M1.6 M1.7 M
Slightly volatile

Werewolf Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation5.4 M8.8 M2.5 M
Slightly volatile
Begin Period Cash Flow103 M155.6 M44.9 M
Slightly volatile
Depreciation930 K1.8 M389.3 K
Slightly volatile
Other Non Cash Items1.2 M1.2 M1 M
Pretty Stable
Capital Expenditures241.3 K254 K537.1 K
Slightly volatile
Issuance Of Capital Stock37.1 M23.6 M32.2 M
Pretty Stable
Total Cash From Financing Activities12.4 M13.1 M32.6 M
Pretty Stable
End Period Cash Flow122.5 M112.2 M59.6 M
Slightly volatile
Change To Liabilities3.7 M3.5 M989.2 K
Slightly volatile
Sale Purchase Of Stock13.7 M14.4 M85.8 M
Slightly volatile
Change To Inventory5.5 M6.2 M6.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio35.7234.0227.7214
Slightly volatile
Days Sales Outstanding26.9928.41130
Slightly volatile
Stock Based Compensation To Revenue4.924.68220.9918
Slightly volatile
Capex To Depreciation0.130.147.276
Slightly volatile
Days Of Inventory On Hand2.0E-43.0E-43.0E-4
Slightly volatile
Payables Turnover27.5226.215.8339
Slightly volatile
Sales General And Administrative To Revenue10.6110.10342.2793
Slightly volatile
Research And Ddevelopement To Revenue31.4429.93856.6304
Slightly volatile
Capex To Revenue0.140.13470.1985
Slightly volatile
Cash Per Share2.732.58971.8006
Slightly volatile
Days Payables Outstanding13.6914.41419
Slightly volatile
Income Quality1.00.79680.9269
Pretty Stable
Net Debt To EBITDA3.141.58052.1479
Slightly volatile
Current Ratio11.087.44849.4396
Pretty Stable
Receivables Turnover6.8613.34.1068
Slightly volatile
Capex Per Share0.00560.00590.018
Slightly volatile
Revenue Per Share0.04130.04350.5019
Slightly volatile
Interest Debt Per Share0.420.36110.295
Slightly volatile
Debt To Assets0.0960.08660.1332
Pretty Stable
Operating Cycle26.9928.41130
Slightly volatile
Days Of Payables Outstanding13.6914.41419
Slightly volatile
Ebt Per Ebit0.740.95820.9727
Slightly volatile
Long Term Debt To Capitalization0.10.11390.0987
Slightly volatile
Quick Ratio11.087.44849.4396
Pretty Stable
Net Income Per E B T1.10.95831.0518
Slightly volatile
Cash Ratio10.877.39239.3078
Very volatile
Days Of Inventory Outstanding2.0E-43.0E-43.0E-4
Slightly volatile
Days Of Sales Outstanding26.9928.41130
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.00451.0355
Slightly volatile
Fixed Asset Turnover0.150.1530.8665
Slightly volatile
Debt Ratio0.0960.08660.1332
Pretty Stable
Price Sales Ratio35.7234.0227.7214
Slightly volatile
Asset Turnover0.01410.01490.0921
Slightly volatile

Werewolf Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap60.9 M64.1 M341.1 M
Slightly volatile

Werewolf Fundamental Market Drivers

Cash And Short Term Investments112.2 M

Werewolf Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Werewolf Therapeutics Financial Statements

Werewolf Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Werewolf Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue816.3 K775.5 K
Total Revenue1.9 M1.8 M
Cost Of Revenue44.7 M47 M
Stock Based Compensation To Revenue 4.68  4.92 
Sales General And Administrative To Revenue 10.10  10.61 
Research And Ddevelopement To Revenue 29.94  31.44 
Capex To Revenue 0.13  0.14 
Revenue Per Share 0.04  0.04 
Ebit Per Revenue(39.04)(37.09)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Werewolf Therapeutics is a strong investment it is important to analyze Werewolf Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Werewolf Therapeutics' future performance. For an informed investment choice regarding Werewolf Stock, refer to the following important reports:
How To Invest In Werewolf
Details
Is Werewolf Stock a good investment?
Details
What is Werewolf Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Werewolf Therapeutics Correlation against competitors.
For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.
You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.63)
Revenue Per Share
0.044
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.30)
Return On Equity
(0.76)
The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY